AstraZeneca AZN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) rendered ...

BeiGene's Tevimbra gets a highly sought after recommendation.

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep ...

RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data ...

The antibiotic can no longer be used in moderate acne vulgaris, eradication of Helicobacter pylori, and prevention of ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

EU regulators have recommended AstraZeneca’s Imfinzi for approval in the treatment muscle-invasive bladder cancer (MIBC).

The new infusion for maple syrup urine disease is for patients who cannot have an oral or enteral branched-chain amino ...

EMA’s human medicine committee recommends approval of GSK’s Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Monday, May 26, 2025, 10:00 Hrs [IST] GSK ...

EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer: Basel Monday, May 26, 2025, 12:00 Hrs [IST] Roche an ...